LYON, France, Nov. 23, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes. The award was presented on November 22, 2010 at a gathering of all major local economic and financial partners.

Marc Oczachowski, Chief Executive Officer, commented, "We are honored to receive this award as it serves as public recognition of EDAP's expertise in the development and innovation of high-end technology. More importantly, this nomination rewards EDAP's teams, who have been fully focused and committed in bringing this innovative device to market. I must say we are all very proud of this revolutionary technology."

"Since its official introduction to the European Urology Community last April in Barcelona, Spain, our Sonolith i-move has been very well received among urologists, who strongly favor its user-friendly concept and technology. As recently as last week at the French Association of Urology (AFU) Congress in Paris, strong interest was expressed in our Sonolith i-move, which was showcased at EDAP's booth and during dedicated demonstrations made to physicians."

Mr. Oczachowski concluded, "While we tend to grow our lithotripsy business with the marketing of our new and innovative range of devices, the regulatory filing processes are progressing well as we pursue Japanese approval and U.S. FDA clearance for our Sonolith i-move."

The innovative Sonolith i-move is a compact and modular lithotripter with a revolutionary infrared stereo-vision system for real-time, three-dimensional ultrasound free line localization of urinary stones. With its various and flexible configurations, the Sonolith i-move offers a wide range of treatment procedures for clinical sites and hospitals. Its patented and unique electro-conductive technology has proved successful and demonstrated the highest efficiency rates, thus definitely bringing significant benefits to patients and users.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

CONTACT:  EDAP TMS SA

          Investor Relations / Legal Affairs

          Blandine Confort

          +33 4 72 15 31 72

          bconfort@edap-tms.com



          The Ruth Group

          Investors:

          Stephanie Carrington

          646-536-7017

          scarrington@theruthgroup.com

News Provided by Acquire Media